<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40053">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736423</url>
  </required_header>
  <id_info>
    <org_study_id>060-CL-703</org_study_id>
    <nct_id>NCT01736423</nct_id>
  </id_info>
  <brief_title>A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome</brief_title>
  <official_title>A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of YM060 once daily for female patients with
      diarrhea-predominant irritable bowel syndrome (D-IBS) for a long-term period (up to 52
      weeks).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Monthly responder rate of global assessment of relief of overall IBS symptoms</measure>
    <time_frame>up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Monthly responder rate of stool form normalization</measure>
    <time_frame>up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Monthly responder rate of global assessment of relief of abdominal pain/discomfort</measure>
    <time_frame>up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Monthly responder rate of global assessment of improvement of abnormal bowel habits</measure>
    <time_frame>up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in weekly average of scores of severity of abdominal pain/discomfort</measure>
    <time_frame>up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in weekly average of scores of stool form</measure>
    <time_frame>up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in weekly average of stool frequency</measure>
    <time_frame>up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of days without urgency</measure>
    <time_frame>up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of days without feeling of incomplete bowel movement</measure>
    <time_frame>up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in entire Japanese version of Irritable Bowel Syndrome Quality of Life (IBS-QOL-J) scores and pairwise IBS-QOL-J scores on the sub-scales</measure>
    <time_frame>4, 8, 12, 28 and 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety assessed through AEs and clinical laboratory values</measure>
    <time_frame>up to 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">151</enrollment>
  <condition>Diarrhea-predominant Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Female Patients with D-IBS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YM060</intervention_name>
    <description>oral</description>
    <arm_group_label>Female Patients with D-IBS</arm_group_label>
    <other_name>Ramosetron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Female patients who meet the following criteria:

          1. Patients satisfying the Rome III Diagnostic Criteria

          2. Patients whose â‰¥25% of stools were loose or watery and &lt;25% of them were hard or
             lumpy stools

          3. Patients who have abdominal pain or discomfort

          4. Patients in whom after occurrence of IBS symptoms the following tests were conducted
             and in whom no organic changes were observed Pancolonoscopy or contrast enema

        Exclusion Criteria:

        Patients who meet any of the following criteria:

          1. Patients with a history of surgical resection of the stomach,gallbladder, small
             intestine or large intestine

          2. Patients with a history or current evidence of inflammatory bowel disease

          3. Patients with a history or current evidence of colitis ischemic

          4. Patients with concurrent infectious enteritis

          5. Patients with concurrent hyperthyroidism or hypothyroidism

          6. Patients with concurrent active peptic ulcer

          7. Patients with other concurrent disease that may affect the digestive tract passage or
             large intestinal function or that is likely to interfere with proper assessment of
             IBS abdominal pain/discomfort
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kantou</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 15, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>YM060</keyword>
  <keyword>Ramosetron</keyword>
  <keyword>long term study</keyword>
  <keyword>Diarrhea-predominant Irritable Bowel Syndrome</keyword>
  <keyword>Female</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
